Welcome to our dedicated page for Alkermes plc news (Ticker: $ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.
Alkermes plc has completed the sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk for approximately $91 million. The sale is part of Alkermes' program to drive operational efficiency and align its infrastructure with business needs. The transaction includes a subcontracting agreement with Novo Nordisk until the end of 2025, expected to be cost-neutral to Alkermes. Post-subcontracting, the sale is anticipated to provide significant operating cost benefits and enhance profitability. Alkermes will retain royalty revenues from products manufactured at the facility while continuing to produce its commercial products in Ohio.
Alkermes plc reported first-quarter 2024 financial results with revenues of $350.4 million, GAAP net income of $38.9 million, and diluted GAAP earnings per share of $0.23. They reiterated their 2024 financial expectations. The company highlighted prescription growth for LYBALVI® and progress with ALKS 2680 for narcolepsy treatment. Key financial highlights include total revenues, profitability, revenue growth for LYBALVI, ARISTADAi, VIVITROL, and royalty revenues. Operating expenses saw an increase due to investments. The company's balance sheet showed cash and total investments of $807.8 million. Alkermes confirmed its financial expectations for 2024 and recent events like new board member appointments, data presentations, and study initiations.